Abbott signs companion Dx development deal with Idera

05/9/2014 | GenomeWeb Daily News (free registration)

Abbott has struck a development deal with Idera Pharmaceuticals for undisclosed terms. The deal calls for Abbott to create a polymerase chain reaction-based assay that can be used as a companion diagnostic test for IMO-8400, Idera's lead drug candidate for certain types of B-cell lymphoma.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY